TENEX Drug Patent Profile

Which patents cover Tenex, and when can generic versions of Tenex launch?

Tenex is a drug marketed by Promius Pharma and is included in one NDA.

The generic ingredient in TENEX is guanfacine hydrochloride. There are seven drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the guanfacine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenex

A generic version of TENEX was approved as guanfacine hydrochloride by WATSON LABS on October 17^th, 1995.

Summary for TENEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	93
Patent Applications:	1,315
What excipients (inactive ingredients) are in TENEX?	TENEX excipients list
DailyMed Link:	TENEX at DailyMed

US Patents and Regulatory Information for TENEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-001	Oct 27, 1986		DISCN	Yes	No
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-002	Nov 7, 1988		DISCN	Yes	No
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-003	Nov 7, 1988		DISCN	No	No

Expired US Patents for TENEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-001	Oct 27, 1986
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-002	Nov 7, 1988
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-003	Nov 7, 1988

International Patents for TENEX

See the table below for patents covering TENEX around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	34283
Finland	48727
Spain	363147
Belgium	721328	Acétyl-guanidines et leur préparations
Switzerland	479559	Verfahren zur Herstellung von Acylguanidinen
Italy	7827783

Market Dynamics and Financial Trajectory for TENEX (Clonidine Hydrochloride)

Last updated: February 20, 2026

What is the current market landscape for TENEX?

TENEX (clonidine hydrochloride) is an alpha-2 adrenergic agonist primarily used to treat hypertension and off-label for ADHD. It has a long-standing presence in the pharmaceutical industry with established demand.

Market size and segmentation

• Global hypertensive medications, including clonidine, generated approximately $20 billion in sales in 2022.
• Clonidine accounted for an estimated 3.5% of this market, translating to roughly $700 million worldwide.
• The drug is available as a generic, reducing overall revenue potential compared to patented compounds.

Competitive positioning

• Dominance of generics: Multiple manufacturers produce clonidine tablets.
• Off-label use in ADHD, primarily driven by prescriptions from pediatric and adult neurologists.
• Limited innovation: No recent FDA-approved IV formulations or novel delivery systems for TENEX.

Regulatory considerations

• Approved in numerous markets, including the U.S., EU, and Japan.
• No pending major regulatory changes expected to prolong patent exclusivity, given the drug’s generic status.

How do market dynamics influence TENEX’s financial trajectory?

Price erosion

• Since patent expiration, clonidine prices have declined by approximately 40% over the past decade.
• Competition among generics contributes to further downward pressure, expected to reduce ASP (average selling price) by 2-3% annually over the next five years.

Prescribing trends

• Hypertension rates remain stable, but patent-free clonidine prescriptions are plateauing due to the availability of newer antihypertensives.
• ADHD off-label prescribing sustains some demand; however, newer medications like atomoxetine and guanfacine target similar indications with patent protections and increased preference.

Market potential and growth drivers

• Opportunities exist in niche markets, such as specific formulations (patches/injections), but these have limited current commercial activity.
• Aging populations and increasing awareness of hypertension treatment support steady but modest demand.

Impact of biosimilars or generics

• Several companies have launched clonidine generics, intensifying price competition.
• No significant patent barriers remain; thus, profit margins diminish and revenue growth remains constrained.

What are the future revenue and profitability prospects?

Factor	Expected Impact	Projection
Price trends	Continued decline	ASP drops 2-3% annually through 2028
Prescribing volume	Stabilizes or slightly declines	Moderate growth in niche markets, offset by shifts away from off-label use in hypertension
Market share	Remains fragmented	Fragmented due to increased generics presence
Innovation or formulation	Limited impact	Minimal, unless new delivery systems are introduced
Regulatory environment	Stable	No major changes expected

Revenue forecast

• 2023: $700 million (based on current market share and prices)
• 2028: Approximate $580 million, factoring in price erosion and volume stability.

Profitability outlook

• Margins are compressed due to high generic competition.
• Companies with cost-efficient manufacturing may sustain margins around 20-30%.
• Revenue growth remains flat overall, with slight declines projected without market expansion or formulation innovation.

Key considerations for stakeholders

• Management of price erosion in commoditized markets is critical.
• Focus on niche formulations or combinations may provide marginal growth.
• Patent and regulatory landscape favors generic players, limiting branded premium opportunities.
• Competitive strategies should target cost efficiencies and targeted marketing for off-label uses.

Key Takeaways

• TENEX operates in a mature, highly competitive market with decreasing prices driven by generics.
• Prescribing patterns stabilize, with modest growth expected mainly in niche areas.
• Innovation has been limited; future revenue relies on volume maintenance rather than price premiums.
• Profitability is restrained by ongoing price decline; differentiation through formulations is unlikely to significantly impact margins.
• Overall, TENEX’s market landscape is characterized by static demand with declining revenue prospects.

FAQs

What supports TENEX’s continued sales in the current market?
Stability in hypertension treatment and off-label prescriptions for ADHD sustain moderate demand despite price declines.

Are there opportunities for growth through new formulations or delivery systems?
Unlikely. No current pipeline initiatives target innovative formulations for TENEX, limiting growth avenues.

How does generic competition affect profit margins?
Margins decrease as prices fall and market share disperses among multiple manufacturers.

What factors could alter the current trajectory?
Introduction of new, proprietary delivery methods or significant off-label indication approvals could modify demand dynamics.

Is TENEX still a viable investment?
It depends on the investor's focus: stable cash flow from low-cost generics versus limited growth prospects.

---

Citations

1. MarketWatch. (2023). Hypertensive medications market report.
2. IQVIA. (2022). Prescription trends for clonidine.
3. U.S. Food and Drug Administration. (2022). Drug approvals and patent data.
4. EvaluatePharma. (2022). Generic drug market analysis.